Jin Xu

Residency Training

Anatomical and Clinical Pathology, UW-Madison

 Fellowship Training

General Surgical Pathology, UW-Madison

Breast Pathology, Memorial Sloan Kettering Cancer Center, NY

Clinical Interests

Breast and Gynecologic Surgical Pathology

Research Interests

Biomarkers in breast pathology

Beta-catenin in gynecological tumors

Selective Publications

• Jin Xu, Molly A. Accola, William M. Rehrauer, Paul S. Weisman. Pilomatrix-like Metaplastic Breast Carcinoma: A Mammary Analog of Pilomatrix-like High-Grade Endometrioid Adenocarcinoma (PiMHEC). Am J Clin Pathol. 2025 Mar 8;163(3):388-394.
• Jin Xu, Paul Weisman. Divergent Malignant Melanocytic Differentiation in Ovarian Endometrioid Adenocarcinoma With Aberrant β-Catenin Expression: A Case Expanding the Histologic Spectrum of β-Catenin Activated Gynecologic Neoplasia. Int J Gynecol Pathol. 2024 May 1;43(3):302-307.
• Jin Xu, Stephanie M McGregor, Kay J Park and Paul Weisman. Ovarian Endometrioid Adenocarcinomas With Infiltrative “Adenofibroma-like” Morphology and Aberrant ß-catenin Expression: Tumors That Coexpress CDX2 and LEF1 With Frequent Neuroendocrine Marker Expression, Diminished/Lost PAX8 and Possible Association With Endometrioid Type II Stem Cell Outgrowths in the Fallopian Tube. Int J Gynecol Path. 2024 Mar 1;43(2):145-148.
• Aysenur Keske, Paul Weisman, Monica Ospina-Romero, Prachi Raut, Kelcy Smith-Simmer, Anna L Zakas, Christopher Flynn, Jin Xu. Breast cancers in monoallelic MUTYH germline mutation carriers have clinicopathological features overlapping with those in BRCA1 germline mutation carriers. Breast Cancer Res Treat. 2024 Feb;204(1):151-158.
• Jin Xu, Kay J Park and Paul Weisman. An Expanded Series of Pilomatrix-like High-Grade Endometrioid Carcinoma (PiMHEC), Including both MMR Deficient and MMR Proficient Cases. Int J Gynecol Path. 2024 Jan 1;43(1):67-69.
• Aysenur Keske, Sindhu Shetty, Paul S Weisman, Qiqi Yu^,, Stephanie McGregor, Jin Xu. A SOX10+/AR- immunoprofile may identify a subset of low positive ER carcinomas with a wider range of ER expression. Pathol Res Pract. 2023 Aug;248:154628.
• Paul Weisman, Qiqi Yu and Jin Xu. Clinicopathological characteristics of the basal subtype of Her2 positive breast cancer as defined by SOX10 positivity. Ann Diagn Pathol. 2023 Apr; 63:152087
• Paul Weisman, Kay J Park, Jin Xu. FIGO grade 3 endometrioid adenocarcinomas with diffusely aberrant ß-catenin expression: An aggressive subset resembling cutaneous pilomatrix carcinomas. Int J Gynecol Path. 2022 Mar 1;41(2):126-131.
• Daniel R. Matson, Molly A. Accola, Les Henderson BA, Xiangqiang Shao, Vanessa L. Horner, William Rehrauer, Paul Weisman and Jin Xu. A “null” pattern of p16 immunostaining in endometrial serous carcinoma: An under-recognized and important aberrant staining pattern. Int J Gynecol Path, 2022 Jul 1;41(4):378-388.
• Jin Xu, Paul Weisman. Dedifferentiated secretory breast carcinoma with fibrosarcomatous features harboring an ETV6-NTRK3 fusion in both components. Genes Chromosomes and Cancer. 2021 Jun;60(6):447-451
• Krystel-Whittemore M*, Jin Xu*, Brogi E, Ventura K, Patil S, Ross DS, Dang C, Robson M, Norton L, Morrow M, Wen HY. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Breast Cancer Res Treat. 2019; 177: 61-66 (*contributed equally to this work)